Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study
1. 系统已在2026-08-17 17:50:54对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s2665-9913(25)00374-1
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2665991325003741
其他信息:
出版社: Elsevier BV
作者: Mikkel Østergaard; Espen A Haavardsholm; Miroslawa Nowak; Yi Luo; Jessica Landis; Aberra Fura; Chahin Pachai; Duncan Rotich; Yanlin Wang-Fischer; Leonidas N Carayannopoulos; David Zammit; Hazem Karabeber; Alice Wang; Dennis M Grasela

